Received Mar 20, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | 7D2Y4 | — |
a 15-month-old patient received a dose of Kinrix on 28/Feb/2025.; Kinrix was the 3rd dose for each (DTap and IPV); This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 15-month-old female patient who received DTPa-IPV (Kinrix) (batch number 7D2Y4, expiry date 22-AUG-2025) for prophylaxis. Previously administered products included Vaxelis (received 1st dose of Vaxelis in May 2024) and Vaxelis (received 2nd dose of Vaxelis in August 2024). On 28-FEB-2025, the patient received the 3rd dose of Kinrix. On 28-FEB-2025, an unknown time after receiving Kinrix, the patient experienced inappropriate age at vaccine administration (Verbatim: a 15-month-old patient received a dose of Kinrix on 28/Feb/2025.) and inappropriate schedule of vaccine administered (Verbatim: Kinrix was the 3rd dose for each (DTap and IPV)). The outcome of the inappropriate age at vaccine administration and inappropriate schedule of vaccine administered were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 10-MAR-2025 On 10-Mar-2025 a reporter reported that vaccine was given prior to the recommended age. Reporter mentioned that a 15-month-old patient received a dose of Kinrix on 28/Feb/2025. Reporter also mentioned that patient received 2 prior doses of Vaxelis for their first 2 doses of DTaP and IPV, one in May and the other in August of 2024, which led to inappropriate schedule of vaccine administered and inappropriate age at vaccine administration. Kinrix was the 3rd dose for each DTap and IPV. The Vaccine Administration Facility is the same as Primary Reporter.